The biotechnology industry has shown resilience in 2023, supported by strong quarterly outcomes, drug approvals, and positive developments despite ongoing economic challenges. The revival of mergers and acquisitions, driven by interest in AI in drug discovery, is bolstering sector momentum as large companies seek to enhance their portfolios. Notable biotech firms like Halozyme Therapeutics, Repligen, Iovance Biotherapeutics, Arcutis Biotherapeutics, and Precigen are well-positioned for growth, supported by innovative technologies and successful drug commercialization strategies. However, pipeline setbacks and geopolitical tensions may pose risks to future prospects, as highlighted by the industry’s current Zacks Rank positioning in the lower segment of performance metrics.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.tradingview.com/news/zacks:ba9561395094b:0-5-biotech-stocks-worth-adding-to-your-portfolio-now/
